Clinical Trials Browser

INDUSTRY × Interventional × ADI PEG20 × Clear all

NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Phase 3 Recruiting

Leiomyosarcoma, Sarcoma

NCT05001828 2026-01-21

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05317819 2025-12-18

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04587830 2025-08-26

GBM

Phase 2 Active not recruiting

Glioblastoma

NCT02709512 2023-10-04

ATOMIC

Phase 2/3 Completed

249 enrolled 17 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03254732 2022-04-27

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Phase 1 Terminated

Advanced Solid Cancers

NCT02102022 2022-04-25

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01910012 2020-10-01

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02101580 2020-10-01

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Advanced Pancreatic Cancer

NCT02029690 2020-09-25

TRAP

Phase 1 Terminated

CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

NCT02875093 2020-03-05

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01287585 2019-09-06

ADI-PEG 20

Phase 3 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01910025 2018-09-18

PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

Phase 2 Completed

Lymphoma, Non-Hodgkin

NCT01497925 2018-09-13

Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT02006030 2018-09-04

TACE

Phase 2 Completed

Gastrointestinal

Liver Neoplasms

NCT01948843 2016-04-14

Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

Phase 1 Completed

HER2 Negative Metastatic Breast Cancer

NCT02101593 2016-03-04

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01665183 2016-02-25

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Phase 1 Completed

DermatologicGynecologic

Uveal Melanoma, Melanoma, Ovarian Neoplasms